Day One Biopharmaceuticals, Inc. (DAWN) has a consensus analyst rating of Buy, based on 12 analysts covering the stock. Of those, 6 recommend buying, 6 recommend holding, and 0 recommend selling.
The analyst consensus price target for DAWN is $23.75, representing a +10.7% upside from the current price of $21.46. Price targets range from a low of $21.50 to a high of $26.00.
